LAUSR

HighlightsDevelopment of stabilising matrix that overcomes low spike recovery problem encountered with Os and Pd.Development of a method that allows the determination of all USP required elemental impurities (As, Cd, Hg, Pb, V, Cr, Ni, Mo, Cu, Pt, Pd, Ru, Rh, Os and Ir) in a single analysis.The method has been successfully validated according to USP <232>/<233> for specificity, accuracy, ruggedness (on different days and a second analyst), linearity and solution stability.Determination of elemental impurities in TP‐6076 active pharmaceutical ingredient (API) by ICP‐MS according to the procedures defined in USP<233> and to GMP requirements.This validation will support the regulatory submission of TP‐6076 which is a novel tetracycline analogue. Abstract The new guidelines of the United States pharmacopeia (USP), European pharmacopeia (EP) and international conference on harmonization (ICH) regulating elemental impurities limits in pharmaceuticals signify the end of unspecific analysis of metals as outlined in USP <231>. The new guidelines specify both daily doses and concentration/limits of elemental impurities in pharmaceutical final products, active pharmaceutical ingredients (API) and excipients. In chapter USP <233> method implementation, validation and quality control during the analytical process are described. We herein report the use of a stabilising matrix that overcomes low spike recovery problem encountered with Os and allows the determination of all USP required elemental impurities (As, Cd, Hg, Pb, V, Cr, Ni, Mo, Cu, Pt, Pd, Ru, Rh, Os and Ir) in a single analysis. The matrix was used in the validation of a method to determine elemental impurities in TP‐6076 active pharmaceutical ingredient (API) by ICP‐MS according to the procedures defined in USP<233> and to GMP requirements. This validation will support the regulatory submission of TP‐6076 which is a novel tetracycline analogue effective against the most urgent multidrug‐resistant gram‐negative bacteria. Evaluation of TP‐6076 in IND‐enabling toxicology studies has led to the initiation of a phase 1 clinical trial.